Pulmonary Fibrosis News Home | Pulmonary Fibrosis News
Dec 10, 2024 · Enzyme responsible for fatty acid may be IPF therapeutic target. Blocking fatty acid synthase (FASN), an enzyme responsible for fatty acid production in cells, reduced the signs of induced idiopathic pulmonary fibrosis (IPF) in mice, according to a study identifying the enzyme as a potential therapeutic target for the condition.
Pulmonary Fibrosis Symptoms, Diagnosis, Prognosis and Treatment
Recent Posts. Trial: LYT-100 better than Esbriet in slowing lung function decline in IPF December 20, 2024; Ways to handle the isolation that can come with the holidays December 17, 2024; Enrollment hits 75% for Phase 2b clinical trial of Haduvio for IPF December 13, 2024; Dealing with grief during a season of joy December 10, 2024; First patient dosed in …
About Us – Pulmonary Fibrosis News
Pulmonary Fibrosis News is a digital platform intended to provide the pulmonary fibrosis (PF) community with the most recent news and information on PF, as well as first-hand community perspectives from our patient and caregiver columnists.. All articles on Pulmonary Fibrosis News are original content produced by in-house writers and editors. . …
12 Facts About Pulmonary Fibrosis Prognosis and Life Expectancy
Aug 16, 2019 · To address some misconceptions about the prognosis of pulmonary fibrosis and life expectancy of patients, we’ve put together some frequently asked questions (and answers) to help:<. What causes pulmonary fibrosis? Some cases of pulmonary fibrosis occur without known cause (this is called idiopathic pulmonary fibrosis).Other cases are caused by exposure to environmental hazards (such as ...
Top 10 Pulmonary Fibrosis Stories of 2021
Jan 3, 2022 · Using a computer-based, artificial intelligence approach, Aria Pharmaceuticals identified two new therapeutic candidates for IPF that showed promising efficacy in a mouse model of the disease. The two compounds, TXR-1002 and TXR-1007, showed in August that they have good tolerability and can reduce lung scarring (fibrosis) and inflammatory cells to a degree at least comparable to that seen ...
New prototype therapy may repair IPF lung scarring by …
Apr 26, 2024 · The study provides pharmacological proof of concept for an upcoming Phase 1 clinical trial that’s evaluating CMR316, an investigational inhalable therapy similar to the designed prototype. “Most drugs act by slowing the progression of disease; our approach is to make drugs that control cell fate to stop or reverse the disease process,” Peter G. Schultz, PhD, president and CEO of Scripps ...
Bexotegrast reverses signs of IPF lung scarring in Phase 2a trial
May 17, 2024 · The Phase 2a imaging study (NCT05621252) enrolled 10 IPF patients. Participants were randomly assigned, with seven receiving 160 mg of once-daily bexotegrast, and three given a matching placebo for 12 weeks.
Study: ENV-101 improves IPF lung function, reverses fibrosis
Jun 7, 2024 · The trial also assessed the effects of treatment on key measures of lung fibrosis as assessed by high-resolution computed tomography (HRCT). Results showed treatment with ENV-101 significantly decreased the absolute percent of quantitative interstitial lung disease — which measures the extent of lung fibrosis — by 9.4%, compared with a 1.1% increase in the placebo.
Now you know: Updates from my journey living with IPF
Nov 5, 2024 · I wanted to take the opportunity this week to update you on topics I’ve discussed in several recent columns. My bronchoscopy. Diagnosed with idiopathic pulmonary fibrosis (IPF) in January 2017, I was fortunate to receive a bilateral lung transplant in July 2021. In December 2022, my care team discovered my left bronchus had narrowed.I underwent several balloon dilations, but these only ...
PF-associated immune cell detected in lungs of people with long...
Oct 18, 2024 · Researchers have identified a type of pro-fibrotic immune cell associated with pulmonary fibrosis (PF) in people who develop persistent breathing problems after recovering from COVID-19. The cells’ abundance correlated with the severity of fibrosis, or tissue scarring, as detected by CT scans.